Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthma
Understanding why patients with severe asthma do not follow healthcare provider (HCP) advice to adjust treatment is critical to achieving personalised disease management. We reviewed patient choice to follow HCP advice to adjust asthma treatment in a UK-based randomised, controlled, single-blind (st...
Saved in:
Published in | The European respiratory journal Vol. 59; no. 4; p. 2100768 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
European Respiratory Society
01.04.2022
|
Subjects | |
Online Access | Get full text |
ISSN | 0903-1936 1399-3003 1399-3003 |
DOI | 10.1183/13993003.00768-2021 |
Cover
Abstract | Understanding why patients with severe asthma do not follow healthcare provider (HCP) advice to adjust treatment is critical to achieving personalised disease management.
We reviewed patient choice to follow HCP advice to adjust asthma treatment in a UK-based randomised, controlled, single-blind (study participant), multicentre, parallel group 48-week clinical study comparing biomarker-directed treatment adjustment with standard care in severe asthma.
Of 1572 treatment advisories (291 participants), instructions were followed in 1377 cases (87.6%). Patients were more likely to follow advice to remain on treatment (96.7%) than to either reduce (70.3%) or increase (67.1%) their treatment, with 64% of patients following all treatment advice. Multivariate analysis associated belonging to an ethnic minority group (OR 3.10, 95% CI 1.68-5.73) and prior study medication changes (two or more changes: OR 2.77, 95% CI 1.51-5.10) with failure to follow treatment advice. In contrast, emergency room attendance in the prior year (OR 0.54, 95% CI 0.32-0.92) was associated with following treatment advice. The largest effect was seen with transition onto or off oral corticosteroids (OR 29.28, 95% CI 16.07-53.36) when compared with those requested to maintain treatment. Centre was also an important determinant regarding the likelihood of patients to follow treatment advice.
Belonging to an ethnic minority group and multiple prior treatment adjustments were associated with not following HCP treatment advice. Patients also responded differently to HCP advice across UK specialist centres. These findings have implications for the generalisability of models of care in severe asthma and require further focused studies. |
---|---|
AbstractList | Understanding why patients with severe asthma do not follow healthcare provider (HCP) advice to adjust treatment is critical to achieving personalised disease management.BACKGROUNDUnderstanding why patients with severe asthma do not follow healthcare provider (HCP) advice to adjust treatment is critical to achieving personalised disease management.We reviewed patient choice to follow HCP advice to adjust asthma treatment in a UK-based randomised, controlled, single-blind (study participant), multicentre, parallel group 48-week clinical study comparing biomarker-directed treatment adjustment with standard care in severe asthma.METHODSWe reviewed patient choice to follow HCP advice to adjust asthma treatment in a UK-based randomised, controlled, single-blind (study participant), multicentre, parallel group 48-week clinical study comparing biomarker-directed treatment adjustment with standard care in severe asthma.Of 1572 treatment advisories (291 participants), instructions were followed in 1377 cases (87.6%). Patients were more likely to follow advice to remain on treatment (96.7%) than to either reduce (70.3%) or increase (67.1%) their treatment, with 64% of patients following all treatment advice. Multivariate analysis associated belonging to an ethnic minority group (OR 3.10, 95% CI 1.68-5.73) and prior study medication changes (two or more changes: OR 2.77, 95% CI 1.51-5.10) with failure to follow treatment advice. In contrast, emergency room attendance in the prior year (OR 0.54, 95% CI 0.32-0.92) was associated with following treatment advice. The largest effect was seen with transition onto or off oral corticosteroids (OR 29.28, 95% CI 16.07-53.36) when compared with those requested to maintain treatment. Centre was also an important determinant regarding the likelihood of patients to follow treatment advice.RESULTSOf 1572 treatment advisories (291 participants), instructions were followed in 1377 cases (87.6%). Patients were more likely to follow advice to remain on treatment (96.7%) than to either reduce (70.3%) or increase (67.1%) their treatment, with 64% of patients following all treatment advice. Multivariate analysis associated belonging to an ethnic minority group (OR 3.10, 95% CI 1.68-5.73) and prior study medication changes (two or more changes: OR 2.77, 95% CI 1.51-5.10) with failure to follow treatment advice. In contrast, emergency room attendance in the prior year (OR 0.54, 95% CI 0.32-0.92) was associated with following treatment advice. The largest effect was seen with transition onto or off oral corticosteroids (OR 29.28, 95% CI 16.07-53.36) when compared with those requested to maintain treatment. Centre was also an important determinant regarding the likelihood of patients to follow treatment advice.Belonging to an ethnic minority group and multiple prior treatment adjustments were associated with not following HCP treatment advice. Patients also responded differently to HCP advice across UK specialist centres. These findings have implications for the generalisability of models of care in severe asthma and require further focused studies.CONCLUSIONSBelonging to an ethnic minority group and multiple prior treatment adjustments were associated with not following HCP treatment advice. Patients also responded differently to HCP advice across UK specialist centres. These findings have implications for the generalisability of models of care in severe asthma and require further focused studies. Understanding why patients with severe asthma do not follow healthcare provider (HCP) advice to adjust treatment is critical to achieving personalised disease management. We reviewed patient choice to follow HCP advice to adjust asthma treatment in a UK-based randomised, controlled, single-blind (study participant), multicentre, parallel group 48-week clinical study comparing biomarker-directed treatment adjustment with standard care in severe asthma. Of 1572 treatment advisories (291 participants), instructions were followed in 1377 cases (87.6%). Patients were more likely to follow advice to remain on treatment (96.7%) than to either reduce (70.3%) or increase (67.1%) their treatment, with 64% of patients following all treatment advice. Multivariate analysis associated belonging to an ethnic minority group (OR 3.10, 95% CI 1.68-5.73) and prior study medication changes (two or more changes: OR 2.77, 95% CI 1.51-5.10) with failure to follow treatment advice. In contrast, emergency room attendance in the prior year (OR 0.54, 95% CI 0.32-0.92) was associated with following treatment advice. The largest effect was seen with transition onto or off oral corticosteroids (OR 29.28, 95% CI 16.07-53.36) when compared with those requested to maintain treatment. Centre was also an important determinant regarding the likelihood of patients to follow treatment advice. Belonging to an ethnic minority group and multiple prior treatment adjustments were associated with not following HCP treatment advice. Patients also responded differently to HCP advice across UK specialist centres. These findings have implications for the generalisability of models of care in severe asthma and require further focused studies. Belonging to a minority ethnic group, multiple prior medication changes, being treated at a specific clinical centre, introduction of systemic corticosteroids and increased asthma symptoms were associated with resistance to asthma treatment modification https://bit.ly/3gYb66S |
Author | Chaudhuri, Rekha Fowler, Stephen J. Pavord, Ian D. Walker, Samantha M. Choy, David F. Howarth, Peter H. Lordan, James L. Woodcock, Ashley Djukanovic, Ratko Matthews, John G. Menzies-Gow, Andrew Brightling, Christopher E. Mansur, Adel H. Cowan, Douglas C. Busby, John Niven, Robert M. Hardman, Timothy C. Robinson, Douglas S. Heaney, Liam G. Arron, Joseph R. Hanratty, Catherine E. Holweg, Cecile T. Bradding, Peter Harrison, Tim W. |
AuthorAffiliation | 5 Niche Science & Technology Ltd, London, UK 3 NHS Greater Glasgow and Clyde Health Board, Gartnavel General Hospital and University of Glasgow, Glasgow, UK 4 Oxford Respiratory NIHR BRC, Nuffield Dept of Medicine, The University of Oxford, Oxford, UK 10 Nottingham Respiratory NIHR Biomedical Research Centre, University of Nottingham, Nottingham, UK 12 The Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne, UK 15 University College Hospitals NHS Foundation Trust, London, UK 1 Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK 9 School of Clinical and Experimental Sciences, University of Southampton, NIHR Southampton Biomedical Research Centre, Southampton, UK 7 Dept of Respiratory Sciences, Institute for Lung Health and Leicester NIHR Biomedical Research Centre, University of Leicester, Leicester, UK 14 Royal Brompton and Harefield NHS Foundation Trust, London, UK 11 Division of Infection, Immunity and Respi |
AuthorAffiliation_xml | – name: 5 Niche Science & Technology Ltd, London, UK – name: 9 School of Clinical and Experimental Sciences, University of Southampton, NIHR Southampton Biomedical Research Centre, Southampton, UK – name: 15 University College Hospitals NHS Foundation Trust, London, UK – name: 2 23 and Me, Sunnyvale, CA, USA – name: 3 NHS Greater Glasgow and Clyde Health Board, Gartnavel General Hospital and University of Glasgow, Glasgow, UK – name: 12 The Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne, UK – name: 4 Oxford Respiratory NIHR BRC, Nuffield Dept of Medicine, The University of Oxford, Oxford, UK – name: 7 Dept of Respiratory Sciences, Institute for Lung Health and Leicester NIHR Biomedical Research Centre, University of Leicester, Leicester, UK – name: 8 NHS Greater Glasgow and Clyde, Stobhill Hospital, Glasgow, UK – name: 11 Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, The University of Manchester, and Manchester Academic Health Science Centre and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester, UK – name: 1 Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK – name: 10 Nottingham Respiratory NIHR Biomedical Research Centre, University of Nottingham, Nottingham, UK – name: 13 University of Birmingham and Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK – name: 6 Genentech Inc., South San Francisco, CA, USA – name: 16 Asthma UK and British Lung Foundation Partnership, London, UK – name: 14 Royal Brompton and Harefield NHS Foundation Trust, London, UK |
Author_xml | – sequence: 1 givenname: John surname: Busby fullname: Busby, John – sequence: 2 givenname: John G. surname: Matthews fullname: Matthews, John G. – sequence: 3 givenname: Rekha surname: Chaudhuri fullname: Chaudhuri, Rekha – sequence: 4 givenname: Ian D. surname: Pavord fullname: Pavord, Ian D. – sequence: 5 givenname: Timothy C. orcidid: 0000-0002-1417-9019 surname: Hardman fullname: Hardman, Timothy C. – sequence: 6 givenname: Joseph R. surname: Arron fullname: Arron, Joseph R. – sequence: 7 givenname: Peter surname: Bradding fullname: Bradding, Peter – sequence: 8 givenname: Christopher E. surname: Brightling fullname: Brightling, Christopher E. – sequence: 9 givenname: David F. surname: Choy fullname: Choy, David F. – sequence: 10 givenname: Douglas C. surname: Cowan fullname: Cowan, Douglas C. – sequence: 11 givenname: Ratko surname: Djukanovic fullname: Djukanovic, Ratko – sequence: 12 givenname: Catherine E. surname: Hanratty fullname: Hanratty, Catherine E. – sequence: 13 givenname: Tim W. surname: Harrison fullname: Harrison, Tim W. – sequence: 14 givenname: Cecile T. surname: Holweg fullname: Holweg, Cecile T. – sequence: 15 givenname: Peter H. orcidid: 0000-0003-0619-7927 surname: Howarth fullname: Howarth, Peter H. – sequence: 16 givenname: Stephen J. orcidid: 0000-0002-4524-1663 surname: Fowler fullname: Fowler, Stephen J. – sequence: 17 givenname: James L. surname: Lordan fullname: Lordan, James L. – sequence: 18 givenname: Adel H. orcidid: 0000-0002-8615-8778 surname: Mansur fullname: Mansur, Adel H. – sequence: 19 givenname: Andrew surname: Menzies-Gow fullname: Menzies-Gow, Andrew – sequence: 20 givenname: Robert M. surname: Niven fullname: Niven, Robert M. – sequence: 21 givenname: Douglas S. surname: Robinson fullname: Robinson, Douglas S. – sequence: 22 givenname: Samantha M. surname: Walker fullname: Walker, Samantha M. – sequence: 23 givenname: Ashley surname: Woodcock fullname: Woodcock, Ashley – sequence: 24 givenname: Liam G. surname: Heaney fullname: Heaney, Liam G. |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34561291$$D View this record in MEDLINE/PubMed |
BookMark | eNp9Uctu1DAUtVArOn18ARLKkk3KdfxIvEFCFQWkSmzo2nLsm45RYg-2ZxB_j8O0FbBgY0v3PO7VOefkJMSAhLyicE3pwN5SphQDYNcAvRzaDjr6gmzWabuOT8gGFLCWKibPyHnO3wCo5Iy-JGeMC0k7RTfE3RpbYsqNmSa0xYeHxrgtJgwWmx--bJuS0JQFQ6nAwdepD41p7OyDt2ausK9vnJqdKb6y8lGV8VBNGpPLdjGX5HQyc8arx_-C3N9--Hrzqb378vHzzfu71nIQpXVDp8zIpROTQylkb63jXFBuDePUsn6EQTI-DghKjKJTk6Osdw4kRcvtwC7Iu6Pvbj8u6Gw9J5lZ75JfTPqpo_H6byT4rX6IB61qeHxg1eDNo0GK3_eYi158tjjPJmDcZ92JXkrBoYNKff3nruclT9FWAjsSbIo5J5yeKRT0WqB-KlD_LlCvBVaV-kdlfanJxvVgP_9X-wvlL6CZ |
CitedBy_id | crossref_primary_10_1038_s41533_024_00391_w crossref_primary_10_3390_app12199890 crossref_primary_10_1016_j_jaip_2022_01_027 crossref_primary_10_1080_24745332_2023_2254283 crossref_primary_10_1016_j_anai_2023_12_023 crossref_primary_10_17925_USRPD_2022_7_2_44 crossref_primary_10_1111_cea_14131 crossref_primary_10_1055_a_1918_8517 crossref_primary_10_1183_13993003_00660_2022 |
Cites_doi | 10.1016/j.jaip.2018.01.025 10.1136/thoraxjnl-2015-207630 10.1136/thoraxjnl-2018-212709 10.1007/s40266-014-0153-9 10.1124/mi.11.2.8 10.1001/archinte.162.15.1761 10.1183/09031936.00075614 10.1186/s12931-018-0742-y 10.1186/s13063-017-2384-7 10.1080/13557850303554 10.1164/rccm.200711-1754OC 10.2147/JAA.S176026 10.1016/S2213-2600(20)30397-0 10.1016/S0140-6736(05)17785-X 10.1016/S0140-6736(17)30879-6 10.1164/rccm.201904-0903SO 10.1016/j.rmed.2020.106156 10.1038/clpt.2014.59 10.1016/j.healthpol.2005.07.022 10.1016/S2213-2600(20)30389-1 |
ContentType | Journal Article |
Copyright | Copyright ©The authors 2022. Copyright ©The authors 2022. 2022 |
Copyright_xml | – notice: Copyright ©The authors 2022. – notice: Copyright ©The authors 2022. 2022 |
CorporateAuthor | investigators for the MRC Refractory Asthma Stratification Programme |
CorporateAuthor_xml | – name: investigators for the MRC Refractory Asthma Stratification Programme |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
DOI | 10.1183/13993003.00768-2021 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1399-3003 |
ExternalDocumentID | PMC9202483 34561291 10_1183_13993003_00768_2021 |
Genre | Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Medical Research Council grantid: MR/M016579/1 – fundername: ; grantid: MR/M016579/1 |
GroupedDBID | --- .55 .GJ 18M 1OC 2WC 31~ 3O- 53G 5GY 5RE 5VS 8-1 AAFWJ AAYXX AAZMJ ABCQX ABJNI ABOCM ABSQV ACEMG ACGFO ACPRK ACXQS ADBBV ADDZX ADMOG ADYFA AENEX AFFNX AFHIN AFZJQ AIZTS AJAOE ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CAG CITATION COF CS3 DIK E3Z EBS EJD F5P F9R GX1 H13 INIJC J5H KQ8 L7B LH4 LW6 OK1 P2P PQQKQ R0Z RHI TER TR2 W8F WOQ X7M ZE2 ZGI ZXP ~02 AADJU CGR CUY CVF ECM EIF NPM 7X8 5PM |
ID | FETCH-LOGICAL-c405t-d829ab46d5fde6567ccd44514ca341c37b08634b8e095b529fd137dd061ec4c83 |
ISSN | 0903-1936 1399-3003 |
IngestDate | Thu Aug 21 18:21:46 EDT 2025 Fri Sep 05 13:44:57 EDT 2025 Sat May 31 02:10:31 EDT 2025 Mon Sep 08 01:41:27 EDT 2025 Thu Apr 24 23:05:03 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Language | English |
License | Copyright ©The authors 2022. This version is distributed under the terms of the Creative Commons Attribution Licence 4.0. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c405t-d829ab46d5fde6567ccd44514ca341c37b08634b8e095b529fd137dd061ec4c83 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
ORCID | 0000-0003-0619-7927 0000-0002-1417-9019 0000-0002-4524-1663 0000-0002-8615-8778 |
OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC9202483 |
PMID | 34561291 |
PQID | 2576654020 |
PQPubID | 23479 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_9202483 proquest_miscellaneous_2576654020 pubmed_primary_34561291 crossref_primary_10_1183_13993003_00768_2021 crossref_citationtrail_10_1183_13993003_00768_2021 |
PublicationCentury | 2000 |
PublicationDate | 2022-04-01 |
PublicationDateYYYYMMDD | 2022-04-01 |
PublicationDate_xml | – month: 04 year: 2022 text: 2022-04-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | The European respiratory journal |
PublicationTitleAlternate | Eur Respir J |
PublicationYear | 2022 |
Publisher | European Respiratory Society |
Publisher_xml | – name: European Respiratory Society |
References | 2024102102391133000_59.4.2100768.10 Bloechliger (2024102102391133000_59.4.2100768.19) 2018; 19 2024102102391133000_59.4.2100768.21 Busby (2024102102391133000_59.4.2100768.7) 2020; 173 2024102102391133000_59.4.2100768.11 2024102102391133000_59.4.2100768.20 2024102102391133000_59.4.2100768.14 2024102102391133000_59.4.2100768.12 2024102102391133000_59.4.2100768.13 Price (2024102102391133000_59.4.2100768.18) 2018; 11 2024102102391133000_59.4.2100768.16 2024102102391133000_59.4.2100768.17 2024102102391133000_59.4.2100768.2 2024102102391133000_59.4.2100768.1 Heaney (2024102102391133000_59.4.2100768.5) 2021; 9 Hanratty (2024102102391133000_59.4.2100768.6) 2018; 19 Bleecker (2024102102391133000_59.4.2100768.3) 2020; 201 2024102102391133000_59.4.2100768.9 2024102102391133000_59.4.2100768.8 Lee (2024102102391133000_59.4.2100768.15) 2021; 9 Heffler (2024102102391133000_59.4.2100768.4) 2018; 6 |
References_xml | – volume: 6 start-page: 776 year: 2018 ident: 2024102102391133000_59.4.2100768.4 article-title: Inhaled corticosteroids safety and adverse effects in patients with asthma publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2018.01.025 – ident: 2024102102391133000_59.4.2100768.2 doi: 10.1136/thoraxjnl-2015-207630 – ident: 2024102102391133000_59.4.2100768.8 doi: 10.1136/thoraxjnl-2018-212709 – ident: 2024102102391133000_59.4.2100768.20 doi: 10.1007/s40266-014-0153-9 – ident: 2024102102391133000_59.4.2100768.10 doi: 10.1124/mi.11.2.8 – ident: 2024102102391133000_59.4.2100768.14 doi: 10.1001/archinte.162.15.1761 – ident: 2024102102391133000_59.4.2100768.17 doi: 10.1183/09031936.00075614 – volume: 19 start-page: 75 year: 2018 ident: 2024102102391133000_59.4.2100768.19 article-title: Adverse events profile of oral corticosteroids among asthma patients in the UK: cohort study with a nested case-control analysis publication-title: Respir Res doi: 10.1186/s12931-018-0742-y – ident: 2024102102391133000_59.4.2100768.1 – volume: 19 start-page: 5 year: 2018 ident: 2024102102391133000_59.4.2100768.6 article-title: A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial publication-title: Trials doi: 10.1186/s13063-017-2384-7 – ident: 2024102102391133000_59.4.2100768.13 doi: 10.1080/13557850303554 – ident: 2024102102391133000_59.4.2100768.21 doi: 10.1164/rccm.200711-1754OC – volume: 11 start-page: 193 year: 2018 ident: 2024102102391133000_59.4.2100768.18 article-title: Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study publication-title: J Asthma Allergy doi: 10.2147/JAA.S176026 – volume: 9 start-page: 57 year: 2021 ident: 2024102102391133000_59.4.2100768.5 article-title: Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(20)30397-0 – ident: 2024102102391133000_59.4.2100768.11 doi: 10.1016/S0140-6736(05)17785-X – ident: 2024102102391133000_59.4.2100768.16 doi: 10.1016/S0140-6736(17)30879-6 – volume: 201 start-page: 276 year: 2020 ident: 2024102102391133000_59.4.2100768.3 article-title: Systematic literature review of systemic corticosteroid use for asthma management publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201904-0903SO – volume: 173 start-page: 106156 year: 2020 ident: 2024102102391133000_59.4.2100768.7 article-title: The effects of oral corticosteroids on lung function, type-2 biomarkers and patient-reported outcomes in stable asthma: a systematic review and meta-analysis publication-title: Respir Med doi: 10.1016/j.rmed.2020.106156 – ident: 2024102102391133000_59.4.2100768.9 doi: 10.1038/clpt.2014.59 – ident: 2024102102391133000_59.4.2100768.12 doi: 10.1016/j.healthpol.2005.07.022 – volume: 9 start-page: 69 year: 2021 ident: 2024102102391133000_59.4.2100768.15 article-title: Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(20)30389-1 |
SSID | ssj0016431 |
Score | 2.4557486 |
Snippet | Understanding why patients with severe asthma do not follow healthcare provider (HCP) advice to adjust treatment is critical to achieving personalised disease... Belonging to a minority ethnic group, multiple prior medication changes, being treated at a specific clinical centre, introduction of systemic corticosteroids... |
SourceID | pubmedcentral proquest pubmed crossref |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 2100768 |
SubjectTerms | Adrenal Cortex Hormones - therapeutic use Asthma - drug therapy Ethnicity Humans Minority Groups Original s Single-Blind Method |
Title | Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthma |
URI | https://www.ncbi.nlm.nih.gov/pubmed/34561291 https://www.proquest.com/docview/2576654020 https://pubmed.ncbi.nlm.nih.gov/PMC9202483 |
Volume | 59 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9QwFLagSFUvqOxDARmJIylJ7EycY1WoClIRoFbqLYqXKFMgU7UZDvz6vmc7jocWBBwmGiVeovm-sd9uQl5lJp9rITkoOa1MuM6ypOGyTVKpTVPkWmQp5g4ffZwfnvAPp8XpZNC32SWD3FU_b8wr-R9U4R7gilmy_4BsGBRuwHfAF66AMFz_CuMDf1hOY4MybLqh7nzdWGdgncLINS4JaN2IsiHdkR0Y8-yqq_pUN9gsDboVLofOr9pnE6eC-f4ictLHb2tzI3zBzjjQNz5Z3MbrhFO99rtmpbuVy3n_Yr52Yav41PzwsffvYca3sYkCtNspssW4ZRXEoISlKYvXXV8JfDEZFa4v5wLLSmBv7Lxr3YbAAJdTHQF8_t0izFAazKts2ttCxOH46Da5k5cgZaH7_vPkbwK5LPM1qWDONzfMuEU2xzHWRZhresmv4bWRvHK8Te56RYPuOdbcI7dMf59sHvlQigdEe_LQQB4ayEORBjSQhzry0EVPGzqSh1ry0GVLR_K4Xo481JHnITk5eHe8f5j4IzcSBZL7kGiRV43kc1202oCoXyqlsYQdVw2IO4qVElRgxqUwIJrLIq9anbFSa5AKjeJKsEdko1_25gmhTEJDwThjMKBWlSgNa-EDepLhqSpnJB9_xVr5evR4LMq32uqlgtUjCrVFoUYUZuR16HTuyrH8ufnLEZ4alk30hTW9Wa4ua9Sz5wUaT2bksYMrDDjiPCPlGpChAZZkX3_SLzpbmr3KsUYge_rbMXfI1vQPeUY2houVeQ5i7SBfWEZeAUshof4 |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Factors+affecting+adherence+with+treatment+advice+in+a+clinical+trial+of+patients+with+severe+asthma&rft.jtitle=The+European+respiratory+journal&rft.au=Busby%2C+John&rft.au=Matthews%2C+John+G&rft.au=Chaudhuri%2C+Rekha&rft.au=Pavord%2C+Ian+D&rft.date=2022-04-01&rft.eissn=1399-3003&rft.volume=59&rft.issue=4&rft_id=info:doi/10.1183%2F13993003.00768-2021&rft_id=info%3Apmid%2F34561291&rft.externalDocID=34561291 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0903-1936&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0903-1936&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0903-1936&client=summon |